NEW YORK, May 15 – Myriad Genetics has received eight foreign patents covering the BRCA1 and BRCA2 breast and ovarian cancer genes and their use in the development of therapeutic and predictive medicine products, the company announced on Tuesday.

The European patent is for “Method for Diagnosing a Predisposition for Breast and Ovarian Cancer” using the BRCA1 and 2 genes. Four Canadian patents, two Australian, and one New Zealand patent cover the BRCA genes. Nine patents had already been issued in the United States, according to the company.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.